HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

geldanamycin

Subscribe to New Research on geldanamycin

unlike the related ansamycins, geldanamycin possesses a methoxyl at C17 on the quinone; from culture filtrates of Streptomyces hygroscopicus var. geldanus var. Nova.

Also Known As:

geldanomycin

Networked: 263 relevant articles (5 outcomes, 29 trials/studies) for this Bio-Agent, Comments

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Neckers, Len: 7 articles (02/2010 - 05/2002)
2.	Chiosis, Gabriela: 5 articles (05/2010 - 02/2003)
3.	Isaacs, Jennifer S: 4 articles (07/2009 - 08/2002)
4.	Sun, Duxin: 4 articles (11/2008 - 01/2005)
5.	Cheng, Hao: 4 articles (11/2008 - 01/2005)
6.	Lai, Yiu-Kay: 4 articles (07/2008 - 04/2005)
7.	Zagzag, David: 4 articles (09/2007 - 08/2003)
8.	Newcomb, Elizabeth W: 4 articles (09/2007 - 08/2003)
9.	Neckers, Leonard M: 4 articles (06/2007 - 08/2002)
10.	Poulaki, Vassiliki: 4 articles (02/2007 - 08/2002)

Related Diseases

1.	Neoplasms (Cancer) 07/01/2005 - "As derivatives of the Hsp90-inhibitor and tumoricidal agent geldanamycin move into phase II clinical trials, its potential for triggering adverse effects in non-tumor cell populations requires closer examination. " 04/01/2010 - "Geldanamycin and its anti-cancer activities." 02/12/2010 - "Deletion of SWE1 in yeast increases Hsp90 binding to its inhibitor geldanamycin, and pharmacologic inhibition/silencing of Wee1 sensitizes cancer cells to Hsp90 inhibitor-induced apoptosis. " 01/01/2010 - "The assay was originally developed to identify inhibitors of Hsp90 in tumor cells, and relies upon the ability of small molecules to inhibit the binding of fluorescently labelled geldanamycin to Hsp90. " 11/01/2009 - "The targetable conjugates can effectively deliver higher amounts of geldanamycin to the tumor compared to nontargetable systems." Order ALL the reference details at left...
2.	Carcinoma (Carcinomatosis) 09/18/2008 - "Geldanamycin promotes premature mitotic entry and micronucleation in irradiated p53/p21 deficient colon carcinoma cells." 12/01/2003 - "Combination treatment with 17-N-allylamino-17-demethoxy geldanamycin and acute irradiation produces supra-additive growth suppression in human prostate carcinoma spheroids." 08/20/2001 - "Both geldanamycin derivatives demonstrated antiproliferative activity towards the human ovarian carcinoma cell line, A2780." 12/15/2003 - "Treatment of two human cervical carcinoma cell lines (HeLa and SiHa) with geldanamycin and 17-AAG resulted in cytotoxicity and, when combined with IR, enhanced the radiation response, each effect with a temporal range from 6 to 48 h after drug exposure. " 11/15/2003 - "Free and N-(2-hydroxypropyl)methacrylamide copolymer-bound geldanamycin derivative induce different stress responses in A2780 human ovarian carcinoma cells." Order ALL the reference details at left...
3.	Infarction 07/07/2006 - "Geldanamycin alone had no effect on infarct size, but it ablated the protection against infarction afforded by diazoxide. " Order ALL the reference details at left...
4.	Burns 12/01/2008 - "Groups included (1) WT shams, (2) CD14 KO sham, (3) WT burns, (4) CD14 KO burns, (5) vehicle-treated WT shams, (6) geldanamycin-treated WT shams, (7) vehicle-treated WT burns, and (8) geldanamycin-treated WT burns. " 12/01/2008 - "Burn covering 40% total body surface area (or sham burn for controls) was produced in wild-type (WT) and CD14 knockout (KO) as well as vehicle-treated and geldanamycin-treated WT mice (1 microg/g body weight) to inhibit CD14 signaling. " 12/01/2008 - "Inability to signal through the CD14/TLR4 pathway (induced by CD14/KO or inhibition of CD14 expression by administration of geldanamycin) attenuated TNF-alpha, IL-1 beta, and IL-6 production in response to burn injury and improved postburn myocardial contractile function. " Order ALL the reference details at left...
5.	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 10/01/2007 - "In this study, the authors describe the development and optimization in a 384-well format of a novel assay for the identification of Hsp90 inhibitors using fluorescence polarization, which measures competitive binding of red-shifted fluorescently labeled geldanamycin (GM-cy3B) to Hsp90 found in the NCI-N417 small-cell lung carcinoma cells. " 04/15/2005 - "In this study we report that the induction of HSP70s is dose-dependent in geldanamycin-treated human non-small cell lung cancer H460 cells. " 12/01/2000 - "Modulation of metastasis phenotypes of non-small cell lung cancer cells by 17-allylamino 17-demethoxy geldanamycin." 12/01/2000 - "The aim of this study was to investigate if depletion of erbB-1/EGFR and erbB-2/HER2neu oncogene products by 17-allylamino 17-demethoxy Geldanamycin (17AAGA) could diminish the metastatic potential of non-small cell lung cancer (NSCLC) cells that express varying levels of the erbB1/erbB2 oncogenes. " 01/01/2010 - "METHODOLOGY/PRINCIPAL FINDINGS: In MTT assays, small cell lung cancer cells showed a biphasic response to the Hsp90 inhibitors geldanamycin and radicicol, with low concentrations causing proliferation arrest and high concentrations causing cell death. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	17-(allylamino)-17-demethoxygeldanamycin (17AAG)
2.	Heat-Shock Proteins (Heat-Shock Protein)
3.	Rifabutin (Ansamycin)
4.	monorden (radicicol)
5.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
6.	Interleukin-1beta (Interleukin 1 beta)
7.	Interleukin-6 (Interleukin 6)
8.	Diazoxide (Hyperstat)
9.	Phosphotransferases (Kinase)
10.	Cisplatin (Platino)

Related Therapies and Procedures

1.	Radiotherapy
2.	Heterologous Transplantation (Xenotransplantation)
3.	Therapeutics
4.	Drug Therapy (Chemotherapy)
5.	Bioreactors

blog comments powered by Disqus

TREATMENT OPTIONS
for Neoplasms,
Ranking and Evidence

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. Analytic charts allow you and your physicians to see at a glance the treatment options—including new, promising, off-label and experimental.

Free Updates for 1 Year
All 21484 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Evidence References
Sample PDF Report on Psoriasis >>

Price:

$8.50 USD & Delivery via PDF download
updates for 1 year

Research Interface PRO

Rapidly retrieve clinical outcome summaries for all evidence of drug efficacy against any disease in seconds. Click "Charts" to view graphs of relative efficacy of all drugs against any known disease. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time. Save hours of search and analysis time:

Two-clicks from Disease to Drug to Evidence: Drill down to full abstract
Enable Experts: Quickly identify key researchers and their publications
Enable FDA Link Generic: Two-clicks to FDA Products/Patents/Generics
Enable Export: All outcome statements and scores exportable to Excel/TSV for automated meta-analysis
Research Network: Explore drug and disease relationships visually
Enable Mobile Interface: Access from your cellphone, iPhone or PDA

Price:

$45.00 USD access via web interface
1 year subscription

Request Bulk Institution License Details >>